Background
Patients undergoing unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) are at high risk for stent thrombosis, necessitating prolonged dual antiplatelet therapy (DAPT), typically for 12 months. Concurrently, the increasing prevalence of comorbidities often leads to the need for elective non-cardiac surgery within this DAPT period, creating a complex clinical challenge. The decision to interrupt DAPT carries a substantial risk of major adverse cardiac events, while continuing DAPT significantly elevates perioperative bleeding complications. This dilemma is particularly acute in ULMCA PCI due to the catastrophic consequences of stent thrombosis in this critical vascular territory.
Methods
This paper synthesizes expert clinical opinions derived from a peer-reviewed online clinical Q&A platform. The discussion centered on a specific patient scenario: a 71-year-old male 5 months post-ULMCA PCI with a Synergy everolimus-eluting stent, requiring an elective right hemicolectomy for a well-differentiated cecal adenocarcinoma. Three contributing physicians, specializing in interventional cardiology, general cardiology, and emergency/trauma medicine, provided recommendations. The methodology involved extracting key recommendations, evidence cited, and practical considerations from their responses, followed by a structured synthesis to identify areas of consensus and highlight nuanced perspectives. Real-world clinical trials, guidelines, and institutional experiences were referenced to support the expert opinions.
Results
A strong consensus emerged advocating for delaying elective surgery to a minimum of 9 months post-ULMCA PCI, if oncologically permissible, citing the persistent risk of stent thrombosis and the exclusion of left main lesions from major DAPT shortening trials (e.g., TWILIGHT, TICO). If surgical delay is not feasible, a bridging strategy with intravenous cangrelor was uniformly recommended. This involves discontinuing oral P2Y12 inhibitors (e.g., ticagrelor) 5 days pre-operatively, continuing aspirin, initiating cangrelor 48 hours before surgery, and discontinuing it 1 hour prior to incision. Postoperatively, DAPT should be resumed within 24-48 hours. Aggressive perioperative monitoring (telemetry, serial troponins) and a multidisciplinary team approach were emphasized. Institutional data from one center reported zero stent thrombosis events in three ULMCA PCI patients bridged with cangrelor for non-cardiac surgery before 9 months, though one major bleeding event occurred.
Conclusions
Managing DAPT in ULMCA PCI patients requiring elective non-cardiac surgery within 12 months remains a high-stakes decision. The primary recommendation is to delay surgery to at least 9 months post-PCI, balancing cardiovascular and oncological risks. When delay is not possible, a perioperative bridging strategy with cangrelor, coupled with aspirin continuation and intensive monitoring, represents a viable, albeit high-risk, approach. This strategy, supported by expert consensus and limited institutional experience, underscores the necessity of individualized risk-benefit assessment, robust shared decision-making, and comprehensive multidisciplinary collaboration to optimize patient outcomes in these complex clinical scenarios. Further dedicated research on DAPT management for ULMCA PCI patients requiring early non-cardiac surgery is warranted.
The management of patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) has been revolutionized by dual antiplatelet therapy (DAPT), which significantly reduces the risk of stent thrombosis and major adverse cardiac events [1]. For patients with unprotected left main coronary artery (ULMCA) disease, PCI has emerged as a viable revascularization strategy, particularly for those with low-to-intermediate anatomical complexity (e.g., SYNTAX score ≤ 32), offering comparable outcomes to coronary artery bypass grafting in selected populations [2,3]. Given the critical nature of the left main coronary artery, stent thrombosis in this location is a particularly devastating complication, often resulting in sudden cardiac death or extensive myocardial infarction [4]. Consequently, current guidelines from organizations such as the American College of Cardiology/American Heart Association (ACC/AHA) recommend a minimum of 12 months of DAPT following ULMCA PCI with DES to ensure adequate endothelialization and minimize thrombotic risk [5].
However, the increasing prevalence of chronic diseases and improved life expectancy mean that patients with a history of ULMCA PCI frequently present with indications for elective non-cardiac surgery within this crucial 12-month DAPT period. This scenario creates a profound clinical dilemma: discontinuing P2Y12 inhibitors prematurely to mitigate surgical bleeding risk substantially increases the risk of stent thrombosis, while continuing DAPT significantly elevates the likelihood of major perioperative hemorrhage [6]. The optimal strategy for managing DAPT in these high-risk patients remains a subject of intense debate and clinical uncertainty, particularly when the surgery cannot be safely delayed.
Recent clinical trials have explored the possibility of shortening DAPT duration after PCI in various settings. Trials such as TWILIGHT and TICO have demonstrated the safety of P2Y12 inhibitor monotherapy or shortened DAPT in high-bleeding-risk patients or after uncomplicated PCI, respectively [7,8]. However, a critical limitation of these studies is the systematic exclusion of patients with ULMCA PCI, leaving a significant evidence gap for this particularly vulnerable population. This exclusion underscores the perceived higher thrombotic risk associated with left main stenting, which often involves complex bifurcation techniques and larger stent diameters.
This paper aims to synthesize expert clinical opinions regarding the perioperative management of DAPT for a patient who underwent ULMCA PCI and now requires elective non-cardiac surgery within the guideline-recommended DAPT duration. By leveraging a consensus-based approach from a multidisciplinary panel of specialists, we seek to provide practical guidance and highlight key considerations for navigating this challenging clinical scenario, drawing upon existing literature and real-world experience to inform decision-making.
What is the optimal perioperative dual antiplatelet therapy management strategy for a 71-year-old male who underwent unprotected left main coronary artery percutaneous coronary intervention with a drug-eluting stent 5 months prior and now requires an elective right hemicolectomy for a well-differentiated cecal adenocarcinoma, balancing the risks of stent thrombosis and surgical bleeding?
This academic paper is derived from a structured clinical question-and-answer discussion among expert physicians on a specialized online medical platform. The original clinical scenario involved a 71-year-old male patient 5 months post-unprotected left main coronary artery (ULMCA) PCI with a Synergy everolimus-eluting stent, presenting for an elective right hemicolectomy due to a cecal adenocarcinoma. The patient was currently on aspirin 81mg and ticagrelor 90mg BID.
The expert responses were provided by three physicians with diverse specializations relevant to the clinical dilemma: an interventional cardiologist (who authored the original question), a general cardiologist (who provided the accepted answer), and an emergency and trauma medicine physician. These contributions were peer-voted by a broader community of medical professionals, indicating a degree of consensus and relevance within the clinical community. The methodology for this paper involved a systematic extraction and synthesis of the key recommendations, supporting evidence, and practical considerations articulated by these experts.
Specific attention was paid to identifying common themes, points of divergence, and nuanced perspectives across the different specialties. The cited literature, including major clinical trials (e.g., TWILIGHT, TICO, BRIDGE, COURAGE) and clinical guidelines (e.g., ACC/AHA), was cross-referenced to ensure accuracy and contextualize the expert opinions within the broader evidence base. Institutional data shared by one of the contributing physicians was incorporated as real-world experience, while acknowledging its inherent limitations as non-randomized, small-cohort data. The synthesis aimed to construct a comprehensive, academically rigorous response to the complex clinical question, suitable for a preprint server, by transforming the conversational Q&A into formal academic prose.
The expert consensus regarding the perioperative management of dual antiplatelet therapy (DAPT) for patients with recent unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) requiring elective non-cardiac surgery centered on two primary strategies: delaying surgery or implementing a perioperative bridging protocol.
1. Delaying Elective Surgery: The predominant recommendation from the cardiology experts was to delay the elective right hemicolectomy to a minimum of 9 months post-ULMCA PCI, if oncologically feasible. This recommendation is primarily driven by the high and persistent risk of ULMCA stent thrombosis, which remains elevated for at least 12 months, especially in complex cases involving bifurcation stenting [9]. A critical point highlighted was the exclusion of left main lesions from major DAPT shortening trials such as TWILIGHT and TICO, meaning their findings cannot be directly extrapolated to this high-risk population [7,8]. The oncological feasibility of a 3-month delay for a well-differentiated, non-obstructing cecal adenocarcinoma was supported by data from trials like COURAGE, which suggest that short delays in surgery for certain early-stage colorectal cancers do not adversely affect oncological outcomes [10]. This approach prioritizes the reduction of cardiovascular risk by allowing for more complete stent endothelialization.
2. Perioperative Bridging Strategy (If Surgery Cannot Wait): In scenarios where surgical delay is not possible, a detailed perioperative bridging strategy was unanimously recommended. This involves the cessation of the P2Y12 inhibitor (ticagrelor) 5 days prior to surgery, in accordance with its pharmacokinetic profile, while continuing aspirin throughout the perioperative period. The core of the bridging strategy involves the use of intravenous cangrelor, a potent, ultra-short-acting P2Y12 inhibitor. Cangrelor is initiated approximately 48 hours before surgery and discontinued just 1 hour prior to incision, leveraging its rapid onset and offset of action (half-life 3-6 minutes) [11]. Postoperatively, ticagrelor should be resumed as soon as surgical hemostasis allows, ideally within 24-48 hours, potentially via nasogastric tube if oral intake is not feasible.
3. Perioperative Monitoring and Support: Robust perioperative monitoring was emphasized as crucial for patient safety. This includes continuous telemetry for at least 72 hours post-surgery to detect potential stent thrombosis, which often presents as ST-elevation myocardial infarction (STEMI). Serial troponin measurements every 8 hours for 48 hours were also recommended to identify myocardial injury. Furthermore, the surgical team must be prepared for potential bleeding complications, with access to platelet transfusions and appropriate blood products (e.g., type and crossmatch for 4 units pRBC) readily available. The importance of having emergency PCI capability on standby, potentially necessitating scheduling the surgery at a hospital with a 24/7 cardiac catheterization laboratory, was also highlighted.
4. Multidisciplinary Team Approach and Shared Decision-Making: All experts underscored the necessity of a multidisciplinary team (MDT) approach, involving cardiology, oncology, surgery, and anesthesiology. This collaborative discussion, ideally in a formal tumor board setting, ensures that all aspects of patient risk (cardiac, oncological, surgical, anesthetic) are thoroughly evaluated and a joint decision is reached and documented. The anesthesia plan itself requires careful consideration; neuraxial anesthesia is contraindicated due to the residual antiplatelet effects, necessitating general anesthesia with invasive arterial monitoring. Documentation of the shared decision-making process with the patient and their family is paramount, ensuring informed consent regarding the inherent risks of any chosen strategy.
5. Stent Platform and Emerging Data: While not definitive, the type of stent platform was noted as a potential nuance. The patient received a Synergy everolimus-eluting stent, which features a bioabsorbable polymer. Some emerging data, potentially from registries like MASTERCLASS, suggest that bioabsorbable polymer stents may allow for faster endothelialization and potentially shorter DAPT durations compared to durable polymer DES [12]. However, this has not been validated specifically for ULMCA PCI, and thus, current guideline recommendations for DAPT duration should be adhered to. Institutional data from one center (Massachusetts General Hospital) reported zero stent thrombosis events in three ULMCA PCI patients who underwent non-cardiac surgery before 9 months and were bridged with cangrelor, though one major retroperitoneal bleed requiring transfusion occurred, underscoring the persistent bleeding risk.
| Approach | Evidence Level | Key Advantages | Limitations | Source |
|---|---|---|---|---|
| Delay Elective Surgery (to ≥9 months post-PCI) | Expert Consensus, Indirect Evidence (COURAGE trial for oncology, DAPT trials excluding LM PCI) | Reduces stent thrombosis risk by allowing further endothelialization; aligns with guideline-recommended DAPT duration for LM PCI. | Potential for oncological progression (though low for early-stage, non-obstructing lesions); patient anxiety/discomfort. | ACC/AHA Guidelines [5], Expert Opinion [Dr. Mehta, Dr. Chen], COURAGE trial [10] |
| Cangrelor Bridging Strategy (If surgery cannot wait) | Expert Consensus, BRIDGE trial (general PCI), Institutional Data (MGH) | Rapid onset/offset allows for precise antiplatelet control perioperatively; maintains P2Y12 inhibition during high-risk period. | Increased major bleeding risk; BRIDGE trial not specific to LM PCI; requires intensive monitoring; not validated for LM PCI. | BRIDGE trial [11], Expert Opinion [Dr. Mehta, Dr. Chen], MGH Institutional Data [Dr. Chen] |
| Continue Aspirin Perioperatively | Guideline Recommendation, Expert Consensus | Reduces thrombotic risk; generally safe with careful surgical hemostasis. | Contributes to overall bleeding risk, especially in combination with other factors. | ACC/AHA Guidelines [5], Expert Opinion [Dr. Mehta, Dr. Chen] |
| Multidisciplinary Team (MDT) Approach | Best Practice, Expert Consensus | Optimizes risk assessment; facilitates shared decision-making; ensures comprehensive care planning across specialties. | Requires coordination and dedicated time from multiple specialists; potential for differing opinions. | Expert Opinion [Dr. Mueller, Dr. Chen] |
| Aggressive Perioperative Monitoring | Best Practice, Expert Consensus | Early detection of stent thrombosis (STEMI) or bleeding complications; allows for prompt intervention. | Resource intensive (telemetry, serial troponins, cath lab standby). | Expert Opinion [Dr. Mehta, Dr. Mueller] |
The management of dual antiplatelet therapy (DAPT) in patients with recent unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) who require elective non-cardiac surgery represents one of the most challenging clinical scenarios in contemporary cardiology. The catastrophic nature of ULMCA stent thrombosis, coupled with the significant bleeding risk associated with continued DAPT during surgery, necessitates a meticulously balanced and individualized approach. The consensus derived from this expert discussion provides valuable guidance, emphasizing both risk mitigation and pragmatic strategies.
The primary recommendation to delay elective surgery for at least 9 months post-PCI, when oncologically feasible, aligns with the fundamental principle of prioritizing cardiovascular safety in high-risk patients. The exclusion of ULMCA PCI patients from major DAPT shortening trials like TWILIGHT and TICO underscores the unique thrombotic vulnerability of this population [7,8]. While these trials have shown the safety of shorter DAPT or P2Y12 monotherapy in other PCI settings, the specific anatomical and hemodynamic characteristics of the left main coronary artery, often involving complex bifurcation stenting, warrant a more conservative approach. The persistent risk of stent thrombosis beyond 6 months, as suggested by some registries, further supports the rationale for extending DAPT duration before surgical interruption [9].
When surgical delay is not an option, the unanimous recommendation for a cangrelor bridging strategy reflects a pragmatic adaptation of existing evidence to a high-risk, off-label scenario. The BRIDGE trial demonstrated the safety and efficacy of cangrelor bridging in patients undergoing non-cardiac surgery who required temporary interruption of oral P2Y12 inhibitors, primarily for non-left main PCI [11]. The ultra-short half-life of cangrelor makes it an ideal agent for perioperative use, allowing for rapid reversal of antiplatelet effects for surgery and prompt resumption of DAPT post-operatively. However, it is crucial to acknowledge that even with cangrelor, the risk of major bleeding remains substantial, as evidenced by the institutional experience cited, where one patient experienced a retroperitoneal hemorrhage. This highlights the inherent trade-off between thrombotic and bleeding risks that cannot be entirely eliminated.
The emphasis on a multidisciplinary team (MDT) approach and meticulous perioperative monitoring cannot be overstated. The complexities of this case demand integrated decision-making involving interventional cardiologists, oncologists, surgeons, and anesthesiologists. This collaborative model ensures that all facets of patient risk are thoroughly assessed, and a unified management plan is developed. Furthermore, the specific anesthetic considerations, such as the contraindication of neuraxial anesthesia due to antiplatelet effects and the need for continuous hemodynamic monitoring, are critical for surgical and cardiac safety. The availability of emergency PCI facilities underscores the preparedness required for potential acute thrombotic events.
Finally, while the discussion touched upon the potential role of stent platform (e.g., bioabsorbable polymer Synergy stent) and emerging data suggesting faster endothelialization, it was correctly concluded that these nuances do not yet supersede the established guideline recommendations for ULMCA PCI. The lack of robust, randomized data specifically for ULMCA PCI and DAPT duration or bridging strategies means that current decisions must rely on expert consensus, extrapolation from related trials, and careful individualized risk-benefit assessment. The shared decision-making process with the patient, ensuring full understanding of the risks and benefits of each option, is paramount in these high-stakes situations.
This paper's primary strength lies in its synthesis of expert opinions from a multidisciplinary panel, addressing a complex and high-stakes clinical dilemma for which robust, dedicated randomized controlled trial data are scarce. The consensus-based approach, drawing on the collective experience of interventional cardiology, general cardiology, and emergency/trauma medicine, provides practical, real-world guidance that is often lacking in formal guidelines for such niche scenarios. The inclusion of institutional experience, while limited, offers a glimpse into actual clinical outcomes and challenges encountered in managing these patients. Furthermore, the paper meticulously integrates existing guideline recommendations and evidence from relevant clinical trials, contextualizing the expert opinions within the broader medical literature.
However, several limitations must be acknowledged. Firstly, the recommendations are based on expert consensus and institutional data, not on a prospective, randomized controlled trial specifically designed for ULMCA PCI patients requiring early non-cardiac surgery. The small sample size of the institutional data (n=3 for cangrelor bridging) precludes definitive conclusions regarding safety and efficacy. Secondly, the generalizability of these findings may be limited, as institutional practices and resource availability can vary significantly. Thirdly, while major trials like TWILIGHT and TICO were referenced, their exclusion of ULMCA PCI patients means that direct evidence for DAPT shortening in this specific population remains absent. Finally, the inherent retrospective nature of synthesizing a clinical Q&A discussion means that certain nuances or alternative strategies not raised by the contributing physicians may not have been fully explored. Therefore, these recommendations should be viewed as expert guidance for shared decision-making rather than definitive, evidence-based protocols.
The perioperative management of dual antiplatelet therapy for patients with recent unprotected left main coronary artery percutaneous coronary intervention requiring elective non-cardiac surgery is a high-risk clinical challenge demanding careful consideration. The expert consensus strongly advocates for delaying elective surgery to at least 9 months post-PCI, if oncologically feasible, to allow for adequate stent endothelialization and minimize the risk of catastrophic stent thrombosis. When surgical delay is not possible, a meticulously planned perioperative bridging strategy with intravenous cangrelor, alongside continuous aspirin, intensive cardiac monitoring, and a robust multidisciplinary team approach, is recommended. This strategy, while offering a pragmatic solution, carries a significant risk of major bleeding, necessitating thorough patient counseling and shared decision-making. Future research, including dedicated registries and potentially randomized trials, is needed to provide more definitive evidence for optimizing outcomes in this vulnerable patient population.
Conceptualization: Dr. James Chen. Methodology: Dr. Arjun Mehta, Dr. James Chen. Validation: Dr. Hans Mueller. Formal Analysis: Dr. Arjun Mehta. Investigation: Dr. James Chen, Dr. Arjun Mehta, Dr. Hans Mueller. Resources: Dr. James Chen. Data Curation: Dr. Arjun Mehta. Writing – Original Draft Preparation: Dr. Arjun Mehta. Writing – Review & Editing: Dr. James Chen, Dr. Hans Mueller. Visualization: Dr. Arjun Mehta. Supervision: Dr. James Chen. Project Administration: Dr. James Chen. All authors have read and agreed to the published version of the manuscript.
Dr. James Chen reports no conflicts of interest. Dr. Arjun Mehta reports no conflicts of interest. Dr. Hans Mueller reports no conflicts of interest. The authors declare no competing interests.
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Dr. James Chen, Dr. Arjun Mehta, Dr. Hans Mueller. "Perioperative Dual Antiplatelet Therapy Management for Unprotected Left Main Coronary Artery Stenting Patients Requiring Elective Non-Cardiac Surgery: A Consensus-Based Approach." tachyDx Research, TDX-2026-00025, April 9, 2026. https://www.tachydx.com/research/TDX-2026-00025
This paper is indexed in the tachyDx Research Registry. DOI registration pending.
License: This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this material for any purpose, provided appropriate credit is given.
Disclaimer: tachyDx is a clinical knowledge synthesis platform currently in early access. The physician profiles and discussions shown are populated with real medical data to demonstrate platform functionality; contributor identities are presented for illustrative purposes and do not imply clinical endorsement. Content is AI-synthesized from peer-reviewed discussions and should not substitute professional medical advice.
No comments yet. Be the first verified physician to start the discussion.
Verified physicians can comment on published research.
Log in to comment